185 related articles for article (PubMed ID: 3598612)
21. Interferon alfa-2a in advanced renal cell carcinoma: treatment results and survival in 159 patients with long-term follow-up.
Minasian LM; Motzer RJ; Gluck L; Mazumdar M; Vlamis V; Krown SE
J Clin Oncol; 1993 Jul; 11(7):1368-75. PubMed ID: 8315435
[TBL] [Abstract][Full Text] [Related]
22. Treatment of renal cell carcinoma with daily low-dose alpha-interferon.
Marshall ME; Simpson W; Butler K; Fried A; Fer M
J Biol Response Mod; 1989 Oct; 8(5):453-61. PubMed ID: 2795090
[TBL] [Abstract][Full Text] [Related]
23. Kaposi's sarcoma and the acquired immunodeficiency syndrome: treatment with high and low doses of recombinant leukocyte A interferon.
Real FX; Oettgen HF; Krown SE
J Clin Oncol; 1986 Apr; 4(4):544-51. PubMed ID: 3958767
[TBL] [Abstract][Full Text] [Related]
24. Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy.
Fyfe G; Fisher RI; Rosenberg SA; Sznol M; Parkinson DR; Louie AC
J Clin Oncol; 1995 Mar; 13(3):688-96. PubMed ID: 7884429
[TBL] [Abstract][Full Text] [Related]
25. Phase I trial of 40-kd branched pegylated interferon alfa-2a for patients with advanced renal cell carcinoma.
Motzer RJ; Rakhit A; Ginsberg M; Rittweger K; Vuky J; Yu R; Fettner S; Hooftman L
J Clin Oncol; 2001 Mar; 19(5):1312-9. PubMed ID: 11230473
[TBL] [Abstract][Full Text] [Related]
26. Antitumor activity of recombinant-derived interferon alpha in metastatic renal cell carcinoma.
Quesada JR; Rios A; Swanson D; Trown P; Gutterman JU
J Clin Oncol; 1985 Nov; 3(11):1522-8. PubMed ID: 4056843
[TBL] [Abstract][Full Text] [Related]
27. Subcutaneous low-dose recombinant interleukin 2 and alpha-interferon in patients with metastatic renal cell carcinoma.
Ravaud A; Négrier S; Cany L; Merrouche Y; Le Guillou M; Blay JY; Clavel M; Gaston R; Oskam R; Philip T
Br J Cancer; 1994 Jun; 69(6):1111-4. PubMed ID: 8198979
[TBL] [Abstract][Full Text] [Related]
28. Phase II trial of intermittent high-dose recombinant interferon alfa-2a in mycosis fungoides and the Sézary syndrome.
Kohn EC; Steis RG; Sausville EA; Veach SR; Stocker JL; Phelps R; Franco S; Longo DL; Bunn PA; Ihde DC
J Clin Oncol; 1990 Jan; 8(1):155-60. PubMed ID: 2295906
[TBL] [Abstract][Full Text] [Related]
29. Safety and tolerance of recombinant interferon alfa-2a (Roferon-A) in cancer patients.
Jones GJ; Itri LM
Cancer; 1986 Apr; 57(8 Suppl):1709-15. PubMed ID: 3948143
[TBL] [Abstract][Full Text] [Related]
30. Recombinant interferon-alpha 2a and vinblastine in advanced renal cell cancer: a clinical phase I-II study.
Kellokumpu-Lehtinen P; Nordman E
J Biol Response Mod; 1990 Aug; 9(4):439-44. PubMed ID: 2395008
[TBL] [Abstract][Full Text] [Related]
31. Phase II trial of interleukin 2, interferon alpha, and 5-fluorouracil in metastatic renal cell cancer: a cytokine working group study.
Dutcher JP; Logan T; Gordon M; Sosman J; Weiss G; Margolin K; Plasse T; Mier J; Lotze M; Clark J; Atkins M
Clin Cancer Res; 2000 Sep; 6(9):3442-50. PubMed ID: 10999727
[TBL] [Abstract][Full Text] [Related]
32. A phase II trial of interleukin-2 and interferon alfa-2a in patients with advanced renal cell carcinoma.
Ilson DH; Motzer RJ; Kradin RL; Vogelzang NJ; Bajorin DF; Scher HI; Nanus D; O'Moore P; Marathias K; Bosl GJ
J Clin Oncol; 1992 Jul; 10(7):1124-30. PubMed ID: 1607918
[TBL] [Abstract][Full Text] [Related]
33. 13-cis retinoic acid and interferon alfa-2a in the treatment of metastatic renal cell carcinoma.
Casali A; Sega FM; Casali M; Serrone L; Terzoli E
J Exp Clin Cancer Res; 1998 Jun; 17(2):227-9. PubMed ID: 9700585
[TBL] [Abstract][Full Text] [Related]
34. Phase II results with recombinant interferons: renal cell carcinoma and malignant melanoma.
Kuzmits R; Kokoschka EM; Micksche M; Ludwig H; Flener R
Oncology; 1985; 42 Suppl 1():26-32. PubMed ID: 4080298
[TBL] [Abstract][Full Text] [Related]
35. Clinical and immunologic effects of subcutaneously administered interleukin-12 and interferon alfa-2b: phase I trial of patients with metastatic renal cell carcinoma or malignant melanoma.
Alatrash G; Hutson TE; Molto L; Richmond A; Nemec C; Mekhail T; Elson P; Tannenbaum C; Olencki T; Finke J; Bukowski RM
J Clin Oncol; 2004 Jul; 22(14):2891-900. PubMed ID: 15254058
[TBL] [Abstract][Full Text] [Related]
36. Phase II study of recombinant interferon alpha-2a and vinblastine in advanced renal cell carcinoma.
Schornagel JH; Verweij J; ten Bokkel Huinink WW; Klijn JG; de Mulder PH; Debruyne FM; van Deijk WA; Roozendaal K; Kok TC; Veenhof KH
J Urol; 1989 Aug; 142(2 Pt 1):253-6. PubMed ID: 2746739
[TBL] [Abstract][Full Text] [Related]
37. Is interferon with or without vinblastine the "treatment of choice" in metastatic renal cell carcinoma? The Norwegian Radium Hospital's experience 1983-1986.
Fosså SD
Semin Surg Oncol; 1988; 4(3):178-83. PubMed ID: 3055161
[TBL] [Abstract][Full Text] [Related]
38. The role of recombinant interferon alfa-2a in the therapy of cutaneous T-cell lymphomas.
Bunn PA; Ihde DC; Foon KA
Cancer; 1986 Apr; 57(8 Suppl):1689-95. PubMed ID: 3485012
[TBL] [Abstract][Full Text] [Related]
39. [Treatment of metastatic renal adenocarcinomas with combined recombinant alpha-2a interferon and vinblastine].
Bergerat JP; Dufour P; Soyer Y; Bollack C; Jacqmin D; Prevot G; Juraschek F; Bailly G; de Garis S; Lang JM
Presse Med; 1987 Nov; 16(39):1953-6. PubMed ID: 2962158
[TBL] [Abstract][Full Text] [Related]
40. Combined interferon and vinblastine treatment of advanced melanoma and renal cell cancer.
Kellokumpu-Lehtinen P; Nordman E
Cancer Detect Prev; 1988; 12(1-6):523-9. PubMed ID: 3180144
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
